How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

235 results for

CCS Symptom Severity in Atrial Fibrillation Scale

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. CCS Symptom Severity in Atrial Fibrillation Scale

CCS Symptom Severity in Atrial Fibrillation Scale CCS Symptom Severity in Atrial Fibrillation Scale Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer (...) Administration 4 CCS Symptom Severity in Atrial Fibrillation Scale CCS Symptom Severity in Atrial Fibrillation Scale Aka: CCS Symptom Severity in Atrial Fibrillation Scale , Canadian Cardiovascular Society SAF Scale , CCS-SAF Scale From Related Chapters II. Symptoms: Used for symptom criteria s Weakness III. Scale Class 0 Asymptomatic Class 1 Symptoms attributable to with minimal effect on patient general quality of life Minimal or infrequent symptoms Single episode of without or Class 2 Symptoms

2018 FP Notebook

2. CCS Symptom Severity in Atrial Fibrillation Scale

CCS Symptom Severity in Atrial Fibrillation Scale CCS Symptom Severity in Atrial Fibrillation Scale Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer (...) Administration 4 CCS Symptom Severity in Atrial Fibrillation Scale CCS Symptom Severity in Atrial Fibrillation Scale Aka: CCS Symptom Severity in Atrial Fibrillation Scale , Canadian Cardiovascular Society SAF Scale , CCS-SAF Scale From Related Chapters II. Symptoms: Used for symptom criteria s Weakness III. Scale Class 0 Asymptomatic Class 1 Symptoms attributable to with minimal effect on patient general quality of life Minimal or infrequent symptoms Single episode of without or Class 2 Symptoms

2016 FP Notebook

3. Atrial Fibrillation Burden: Moving Beyond Atrial Fibrillation as a Binary Entity: A Scientific Statement From the American Heart Association

Atrial Fibrillation Burden: Moving Beyond Atrial Fibrillation as a Binary Entity: A Scientific Statement From the American Heart Association Atrial Fibrillation Burden: Moving Beyond Atrial Fibrillation as a Binary Entity: A Scientific Statement From the American Heart Association | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January (...) 2019 January 2019 January 2019 January 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Atrial Fibrillation Burden: Moving Beyond Atrial Fibrillation as a Binary Entity: A Scientific Statement From the American Heart Association , MD, MS, FAHA, Chair , MD, FAHA, Vice Chair , MD, MHS, FAHA , MBChB, DPhil, FAHA , MD, MPH, FAHA , PhD, RN , MD , and MD MD, MASOn behalf

Full Text available with Trip Pro

2018 American Heart Association

4. Atrial Fibrillation

Study LV left ventricular LVEF left ventricular ejection fraction LVH left ventricular hypertrophy MANTRA-PAF Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation MERLIN Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndromes MRA Mineralocorticoid receptor antagonist MRI magnetic resonance imaging NIHSS National Institutes of Health stroke severity scale NOAC non-vitamin K antagonist oral anticoagulant NOAH Non (...) Screening for atrial fibrillation by electrocardiogram in the community 17 5.2.2 Prolonged monitoring for paroxysmal atrial fibrillation 17 5.2.3 Patients with pacemakers and implanted devices 17 5.2.4 Detection of atrial fibrillation in stroke survivors 18 5.3 Electrocardiogram detection of atrial flutter 19 6 Classification of atrial fibrillation 19 6.1 Atrial fibrillation pattern 19 6.2 Atrial fibrillation types reflecting different causes of the arrhythmia 20 6.3 Symptom burden in atrial

Full Text available with Trip Pro

2016 European Society of Cardiology

5. Atrial Fibrillation - Diagnosis and Management

for newly detected non-valvular AF (see ). 1. How symptomatic is the patient? 2. Should an anticoagulant be used for stroke prevention? 3. Is this a rate or rhythm control strategy? Figure 1. Management of newly detected non-valvular atrial fibrillation STEP 1: How symptomatic is the patient? Determine the patient’s cardiac stability and provide emergency stabilization if needed. Consider utilizing the Canadian Cardiovascular Society Severity of Atrial Fibrillation (CCS-SAF) scale to assess AF symptom (...) the patient’s cardiac stability and provide emergency stabilization if needed. Consider all patients with atrial fibrillation for antithrombotic therapy (short and long term). Establish the risk of stroke in patients with atrial fibrillation using age (≥ 65) and CHADS 2 . Oral anticoagulants are recommended in patients with CHADS 2 = 0 and age ≥ 65 years. The goals of rate and/or rhythm control strategies are to improve patient symptoms, exercise tolerance, quality of life, prevent hospitalizations

2015 Clinical Practice Guidelines and Protocols in British Columbia

6. Atrial Fibrillation ? Diagnosis and Management

about palpitations and check for irregular heart rhythm during a routine exam in patients at risk for stroke. 2,14,15 For patients who present with the above symptoms, ascertain if any of these symptoms are present during AF. If so, they are likely caused by AF. Refer to Appendix C: Assessing Atrial Fibrillation Symptom Severity with the CCS-SAF Scale. A pulse check that detects an irregularity can be confirmed by an electrocardiogram (ECG). 2 Ambulatory ECG monitoring (e.g., Holter (...) Fibrillation Symptom Severity with the CCS-SAF Scale • Appendix D: Stroke Risk Assessment in Atrial Fibrillation: CHADS 2 Score • Appendix E: HAS-BLED Score for Major Bleeding • Appendix F: Comparisons of Anticoagulants for Atrial Fibrillation • Appendix G: Prescription Medication Table for Atrial Fibrillation Associated Documents The following documents accompany this guideline: • BCGuidelines.ca – Stroke and Transient Ischemic Attack – Acute and Long-Term Management • BCGuidelines.ca – Use of Non-Vitamin

2015 Clinical Practice Guidelines and Protocols in British Columbia

7. Anticoagulation adherence and its associated factors in patients with atrial fibrillation: a cross-sectional study. (PubMed)

Anticoagulation adherence and its associated factors in patients with atrial fibrillation: a cross-sectional study. To investigate anticoagulant adherence and its associated factors, including demographics, clinical variables, atrial fibrillation (AF) severity, knowledge, satisfaction with services, perceived barriers, perceived benefits, symptom severity and self-efficacy in patients with AF.This is a cross-sectional study.A convenient sample of patients with AF were recruited from cardiology (...) clinics of two teaching hospitals in Taiwan.Data were collected using the study questionnaires, including the AF-related symptom subscale of the AF Severity Scale, the Knowledge of Warfarin Anticoagulation Treatment Scale, the Satisfaction Scale about Service and Warfarin Treatment, the perceived benefits subscale of the Beliefs about Anticoagulation Survey, the Concerns about Anticoagulation Therapy Scale, The Self-efficacy for Appropriate Medication Use Scale and the short-form Adherence to Refills

2019 BMJ open

8. CCS/CHRS 2016 Implantable Cardioverter-Defibrillator (ICD) Guidelines

Comorbidities can increase the risk of SCD and, as such, the derived benefit of an ICD, and also increase the risk of nonarrhythmic death resulting in lesser benefit. Those shown to increase nonarrhythmic death in ICD recipients are diuretic use, older age, increased NYHA class, hypertension, atrial fibrillation, increased QRS duration, LVEF < 30%, nonprescription use of a β-blocker, reduced heart rate variability, low serum sodium, chronic lung disease, peripheral vascular disease, diabetes, and chronic (...) vascular disease, dementia, chronic pulmonary disease, connective tissue disease, peptic ulcer disease, liver disease, diabetes, hemiplegia, renal disease, leukemia/lymphoma, metastatic tumour Age Atrial fibrillation New York Heart Association class Serum sodium Heart Rate Variability ICD, implantable cardioverter defibrillator. Frailty There are many methods of estimating frailty. Table 2 shows a global assessment tool in which the clinician makes a gestalt judgement about the patient's frailty

2016 Canadian Cardiovascular Society

9. Exercise Training in Patients With Persistent or Permanent Atrial Fibrillation

by the Canadian Cardiovascular Society Severity of Atrial Fibrillation Scale from baseline to 12 weeks.The CCS-SAF is a simple, concise, symptom-based severity scale to assess patient status. CCS-SAF scores range from 0 to 4, with highest values denoting severe impact of symptoms on quality of life and activities of daily living. The CCS-SAF has been validated in patients with atrial fibrillation. Changes in quality of life measured by the mental component summary (MCS) measure of the Short Form 36 Health (...) . Patients will assess the impact of AF on their health status during the previous 4 weeks. Responses are presented as a 7-point Likert scale. Raw scores within each domain are transformed to a 0 (most severe symptoms) to 100 scale (no limitations or disability). The AFEQT is valid, reliable and sensitive to clinical change in patients with AF undergoing different therapeutic interventions. Changes atrial fibrillation specific quality of life measured by the University of Toronto Atrial Fibrillation

2018 Clinical Trials

10. Hybrid Therapy and Heart Team for Atrial Fibrillation

epicardial surgical ablation. The validation will be performed during catheter ablation: isolation will be validated if there an entrance block in the posterior wall and in the pulmonary veins. Evolution of quality of life [ Time Frame: Between baseline to 12 months ] Evolution of quality of life using the Canadian Cardiovascular Society Severity in Atrial Fibrillation (CCS-SAF) scale. Symptom severity, physical and emotional components of quality of life, general well-being, and health care consumption (...) Hybrid Therapy and Heart Team for Atrial Fibrillation Hybrid Therapy and Heart Team for Atrial Fibrillation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Hybrid Therapy and Heart Team for Atrial

2018 Clinical Trials

11. Atrial Fibrillation Lifestyle Project

in Atrial Fibrillation Scale (CCS-SAF), and the Atrial Fibrillation Symptom Severity Scale (AFSS). The CCS-SAF categorizes severity of atrial fibrillation from Class 0 to Class 4, with 0 being asymptomatic and 4 being severe. On the AFSS, individual symptoms attributable to AF are scored on a five-point Likert scale, such that the total AFSS severity score ranges from 0 to 35, with higher scores indicating increased AFSS. These two scales will be used simultaneously to inform the severity of Atrial (...) exercise program The interval and resistance training program will mirror the supervised exercise. Outcome Measures Go to Primary Outcome Measures : Changes in frequency of atrial fibrillation [ Time Frame: Baseline to 6 months and 1 year ] The frequency of AF will be measured with 48-hour Holter monitor recording, looking at percent of time in AF. Changes in severity of atrial fibrillation [ Time Frame: Baseline to 6 months and 1 year ] Assessed using the Canadian Cardiovascular Society Severity

2018 Clinical Trials

12. Atrial Fibrillation

. This arrhythmia is a major cardiovascular challenge in modern society and its medical, social and economic aspects are all set to worsen over the coming decades. Fortunately a number of valuable treatments have been devised in recent years that may offer some solution to this problem. In 2010, when the ESC Guidelines for the Management of Atrial Fibrillation were ?rst issued, 1 it was already realized that an update would be necessary in 2012 because, for example, European regu- latory approvals of several (...) heart failure, and should be avoided in patients with less-severe heart failure, if appropriate alternatives exist. 8. Catheter ablation of atrial ?brillation 8.1 New evidence for catheter ablation Since the publication of the ESC AF Guidelines in 2010, several new sets of data have become available. The randomized MANTRA-PAF (Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation) 156 trial compared catheter ablation of AF to antiarrhythmic drug therapy

2012 European Society of Cardiology

13. Characterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation

will have a clinical follow up visit at 3, 6, and 12 months after the ablation procedure. A 14-day continuous ambulatory ECG monitor will be completed at each visit. The results of monitoring will be interpreted at a centralized core lab, and the results will be adjudicated by an arrhythmia specialist blinded to treatment group. A total of three questionnaires will be administered throughout the study, each at a specific time point. The Quality of Life (EQ-5D), CCS-Severity of AF scale, and Atrial (...) general quality of life score, and AF severity scale (symptoms and functionality) Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages

2017 Clinical Trials

14. Management of Atrial Fibrillation

in Atrial Fibrillation; EHRA = European Heart Rhythm Association. 6 Table 4: Relevant questions to be put to a patient with suspected or known AF AF = atrial fibrillation; CCS-SAF = Canadian Cardiovascular Society Severity in Atrial Fibrillation; EHRA = European Heart Rhythm Association. Does the heart rhythm during the episode feel regular or irregular? Is there any precipitating factor such as exercise, emotion, or alcohol intake? Are symptoms during the episodes moderate or severe—the severity may (...) of blood pressure will be a good opportunity to pick up undiagnosed atrial fibrillation. In patients presenting with any of the following: x breathlessness/dyspnoea, x palpitations, x syncope/dizziness, x chest discomfort or stroke/TIA, manual pulse palpation should be performed to assess for the presence of an irregular pulse that may indicate AF. Table 4: Relevant questions to be put to a patient with suspected or known AF AF = atrial fibrillation; CCS-SAF = Canadian Cardiovascular Society Severity

2012 Ministry of Health, Malaysia

15. Detection of Silent Atrial Fibrillation aFter Ischemic StrOke

vessel ultrasonography and/or CT-Angiography and/or MR-Angiography, also in order to rule out non-atherosclerotic vasculopathies; thrombophilic/hematologic screening if hypercoagulability states or other hematologic disorders are suspected). Neurological severity in terms of functional dependency defined as mRS (modified Rankin Scale) score ≤3. Written informed consent. Exclusion Criteria: TIA without evidence of cerebral infarction on neuroimaging corresponding to patient symptoms. Diagnosis (...) Detection of Silent Atrial Fibrillation aFter Ischemic StrOke Detection of Silent Atrial Fibrillation aFter Ischemic StrOke - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Detection of Silent Atrial

2016 Clinical Trials

16. Reversal of Atrial Substrate to Prevent Atrial

number of stoke or systemic embolism events. Quality of Life - CCS-SAF [ Time Frame: Up to 24 months ] Symptom burden as measured by the Canadian Cardiovascular Society (CCS) Severity of Atrial Fibrillation (SAF) scale. CCS-SAF scores range from 0 to 4, with higher values representing more severe impact of symptoms on quality of life and activities of daily living. Quality of Life - AFEQT [ Time Frame: Up to 24 months ] Quality of life as measured by the Atrial Fibrillation Effect on QualiTy-of-life (...) information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Patients with symptomatic (CCS-SAF ≥2) paroxysmal or persistent atrial fibrillation despite rate control, desiring catheter ablation and at least two of the following: BMI>27, BP>140/90 mmHg or history of hypertension, Prior stroke/transient ischemic attack, Diabetes, Heart failure (prior heart

2018 Clinical Trials

17. Menopausal Symptoms: Comparative Effectiveness of Therapies

therapies 14 Table 4. Minimal clinically important difference (MCID) or minimal clinically important improvement (MCII) for various scales 21 Table 5. Downgrading of SOE according to domains from the initial SOE of high (3 points) to moderate (2 points), low (1 point), or insufficient (0 points) 22 xi Table 6. Agents and categorizations for purposes of review 26 Table 7. Comparison matrix example. 30 Table 8. Characteristics of trials assessing efficacy of treatment on vasomotor symptoms 34 Table 9 (...) to stabilization of low estradiol levels. 2 Approximately 85 percent of women report experiencing symptoms of varying type and severity during menopause. 3 Types of symptoms experienced may include 1 — • Vasomotor symptoms: Hot flushes are recurrent, transient episodes of intense heat in the face and upper body, sometimes followed by chills. These symptoms can occur while sleeping, producing intense perspiration. Individual hot flushes may last from 1 to 5 minutes. After irregular menses, vasomotor symptoms

2015 Effective Health Care Program (AHRQ)

18. Carvedilol for Prevention of Paroxysmal Atrial Fibrillation

and 50 mg bid respectively. AF occurrence will be documented using event recorders. The co-primary outcome measures are survival free from AF after one month blanking period for drug titration and the number of days in AF detected during follow-up. Secondary outcomes include event free survival to first symptomatic episode of AF, days in symptomatic AF, time between first and second episodes of AF, proportion of patients who develop persistent AF, AF Severity Scale, CCS-AF symptom score, ventricular (...) Collaborators: Heart and Stroke Foundation of Canada Libin Cardiovascular Institute of Alberta Information provided by (Responsible Party): Dr. Anne M. Gillis, University of Calgary Study Details Study Description Go to Brief Summary: Atrial fibrillation (AF) is the most common sustained heart rhythm disorder and is associated with significant symptoms and health problems including an increased risk of stroke and death. Current drug therapies are often ineffective and associated with significant side

2012 Clinical Trials

19. Ablation procedures for rhythm control in patients with atrial fibrillation: clinical and cost-effectiveness analyses

Procedures Questionnaire Ablation Procedures for Rhythm Control in Patients with Atrial Fibrillation: Clinical and Cost-Effectiveness Analyses x ACRONYMS AND ABBREVIATIONS AAD antiarrhythmic drug ACC American College of Cardiology AF atrial fibrillation AHA American Heart Association AT atrial tachycardia or tachyarrhythmia AV atrioventricular CADTH Canadian Agency for Drugs and Technologies in Health CCS Canadian Cardiovascular Society CFAEs complex fractionated atrial electrograms CHF congestive heart (...) . Population Adults (18 years of age or older) with AF, regardless of duration or severity of symptoms. Interventions Minimally invasive ablation procedures that convert AF to NSR: pulmonary vein isolation (PVI) ablation (catheter-based approach aiming at applying energy to cardiac electrical pathways [hot spots] originating from PVs to interrupt arrhythmogenic activity), PVI plus atrial ablation, minimally invasive surgical procedure and minimal access catheter Maze procedure (a probe is inserted through

2010 EvidenceUpdates

20. Guidelines on Chronic Coronary Syndromes

a day); PCI = percutaneous coronary intervention; PCSK9 = proprotein convertase subtilisin-kexin type 9; VKA = vitamin K antagonist. a Class of recommendation. ACE = angiotensin-converting enzyme; ACS = acute coronary syndromes; AF = atrial fibrillation; b.i.d. = bis in die (twice a day); CAD = coronary artery disease; CCS = chronic coronary syndromes; CHA 2 DS 2 -VASc = Cardiac failure, Hypertension, Age ≥75 [Doubled], Diabetes, Stroke [Doubled] – Vascular disease, Age 65–74 and Sex category (...) 3.2.2.9 Adherence and sustainability 25 3.2.2.10 Influenza vaccination 25 3.3 Pharmacological management 26 3.3.1 Anti-ischaemic drugs 26 3.3.1.1 General strategy 26 3.3.1.2 Available drugs 26 3.3.1.3 Patients with low blood pressure 29 3.3.1.4 Patients with low heart rate 29 3.3.2 Event prevention 30 3.3.2.1 Antiplatelet drugs 30 3.3.2.2 Anticoagulant drugs in sinus rhythm 30 3.3.2.3 Anticoagulant drugs in atrial fibrillation 31 3.3.2.4 Proton pump inhibitors 31 3.3.2.5 Cardiac surgery

Full Text available with Trip Pro

2019 European Society of Cardiology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>